Boehringer Ingelheim Limited: Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

• Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.
• The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.
• The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease control by reducing targeted B cell populations.

Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 - Boehringer Ingelheim and Cue Biopharma, Inc.? and follow us on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

[e-mail]

Cue Biopharma Investor Contact:

Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.

[e-mail]

Cue Biopharma Media Contact:

Jonathan Pappas
LifeSci Communications

[e-mail]